Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2 Plasmacytoma 1 Peripheral Nervous System Diseases 1 Ovarian Neoplasms 1 Neoplasms 1 Multiple Myeloma 1 Lymphedema 1 Fallopian Tube Neoplasms 1 Disease Progression 1 Breast Neoplasms 1 Arsenic Poisoning 1

Interventions

Lenalidomide 4 Gemcitabine 4 Dexamethasone 4 Cyclophosphamide 4 Bortezomib 4 Nivolumab 3 Cisplatin 3 Carboplatin 3 vandetanib 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 pomalidomide 2 pembrolizumab 2 liposomal doxorubicin 2 fludarabine 2 durvalumab 2 capivasertib 2 Paclitaxel 2 Doxorubicin 2 Bevacizumab 2 venetoclax 1 umbralisib 1 ublituximab 1 tremelimumab 1 tivozanib 1 ricolinostat 1 regorafenib 1 pazopanib 1 niraparib 1 nilotinib 1 neratinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Disease Progression × Sodium Selenite × Clear all

NCT01959438 2013-10-10

SECAR

Karolinska University Hospital

Phase 1/2 Unknown

Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡